Benzinga · Apr 21, 2022
Ampio Pharma Shares Fall As FDA Rejects Proposed Change In Knee Osteoarthritis Trial
Ampio Pharmaceuticals Inc (NYSE: AMPE) received written responses from the FDA pursuant to a Type C meeting request regarding the AP-013 Phase 3 trial results. In March, Ampio announced data from the modified Intent-To-Treat (mITT) population (n=618) in the AP-013 study of Ampion in severe osteoarthritis of the knee (OAK). Ampion demonstrated a statistically significant reduction in pain (p=0.042) and trended favorably toward improving ...Full story available on Benzinga.com
